CP and chronic myelogenous leukemia, BCR-ABL1 positive: Among patients with CML-CP without BCR::ABL1T315I, major molecular response (MMR [BCR::ABL1 ≤ 0.1% on the International Scale (IS)]) was achieved or maintained by year 1 in 44 of 91 evaluable patients (48%), demonstrating preliminary efficacy [30].